Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis

Abstract

BackgroundPatients on hemodialysis (HD) are most likely to contract hepatitis C (HCV) infection, which is associated with significant morbidity and disease progression. Direct-acting antivirals (DAAs) are safe and tolerable in chronic kidney disease (CKD) with a 90-100% cure rate, and limited data exist regarding their efficacy in end-stage renal disease (ESRD), particularly for HD patients in South Asia.The study aimed to assess the outcome of a 12-week sofosbuvir (SOF) and velpatasvir (VEL) treatment regimen on ESRD patients with chronic HCV infection undergoing HD in the Pakistani Asian population. Methodology

Efficacy of Sofosbuvir and Velpatasvir Combination in the Treatment of Hepatitis C Virus (HCV) in Chronic Kidney Disease (CKD) Patients

“…Our study results are also comparable to the study results done by Gaur et al in India wherein an SVR12 was achieved in 96.8% of participants of the study [16] and to the results of a study done by Shahid et al in Sheikh Zayed Hospital Rahim Yar Khan, wherein SVR was achieved in 91% CKD patients who were having an HCV infection and were treated with sofosbuvir and velpatasvir combinations [17]. The findings of this descriptive study are also consistent with the study results in efficacy, done by Borgia et al where they enrolled 59 CKD patients having chronic hepatitis C infection, and a combination of sofosbuvir and velpatasvir was given, and 56 (95%) patients achieved SVR12 [18].…”